Intra-Cellular Therapies Profit Margin 2013-2022 | ITCI
Current and historical gross margin, operating margin and net profit margin for Intra-Cellular Therapies (ITCI) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Intra-Cellular Therapies net profit margin as of September 30, 2022 is -158.39%.
| Intra-Cellular Therapies Annual Profit Margins |
| Intra-Cellular Therapies Quarterly Profit Margins |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$4.619B |
$0.084B |
|
Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.
|
